Understanding mechanisms controlling fluid injection-triggered seismicity is key in defining strategies to ameliorate it. Recent triggered events (e.g. Pohang, Mw 5.5) have exceeded predictions of average energy release by a factor of >1000x, necessitating robust methodologies to both define critical antecedent conditions and to thereby constrain anticipated event size. We define maximum event magnitudes resulting from triggering as a function of pre-existing critical stresses and fluid injection volume. Fluid injection experiments on prestressed laboratory faults confirm these estimates of triggered moment magnitudes for varied boundary conditions and injection rates. In addition, observed ratios of shear slip to dilation rates on individual faults signal triggering and may serve as a measurable proxy for impending rupture. This new framework provides a robust method of constraining maximum event size for preloaded faults and unifies prior laboratory and field observations that span sixteen decades in injection volume and four decades in length scale.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943564 | PMC |
http://dx.doi.org/10.1038/s41467-020-20700-4 | DOI Listing |
J Cancer Res Ther
December 2024
Department of Ultrasound, The Third Affliated Hospital of Sun Yat-sen University, Guangzhou City, Guangdong Province, China.
Purpose: To evaluate the risk factors that may delay enhanced recovery in the ablation of liver tumors.
Methods: A total of 310 patients who underwent ultrasound-guided ablation of liver tumors under general anesthesia were prospectively enrolled. Baseline data, intraoperative parameters, and postoperative events were evaluated.
J Hypertens
December 2024
Division of Cardiology, Department of Internal Medicine, Korea University Guro Hospital, Seoul, Republic of Korea.
Background: People with diabetes often have increased blood pressure (BP) variability because of autonomic dysfunction and arterial stiffness, making it a critical factor in predicting clinical outcomes. We investigated the reproducibility of long-term visit-to-visit BP variability (VVV) and the minimum number of BP readings to reliably determine VVV in people with diabetes.
Methods: This multicenter retrospective study used data from electronic health records of the Korea University Medical Center database.
Clin Pharmacol Drug Dev
January 2025
Department of Clinical Pharmacology, Aerospace Center Hospital, Beijing, China.
This study aimed to evaluate the pharmacokinetic characteristics, safety, and bioequivalence of 2 formulations of fluticasone nasal spray in healthy Chinese subjects. A single-center, randomized, open-label, single-dose, 2-formulation, 2-sequence, 2-period crossover bioequivalence study was conducted under fasting conditions. A total of 120 healthy male and female subjects were enrolled, of which 119 subjects completed the entire study.
View Article and Find Full Text PDFClin Pharmacol Drug Dev
January 2025
Allergy & Asthma Solutions, Coto de Caza, CA, USA.
The primary objective of the study was to determine the bioavailability of 2 new formulations of azelastine (AZE) hydrochloride (0.10% and 0.15% AZE) containing sorbitol and sucralose compared with the commercially available 0.
View Article and Find Full Text PDFJ Transl Med
January 2025
Scientia Clinical Research and Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, 2052, Australia.
Background: A novel anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC) GQ1001 was assessed in patients with previously treated HER2 positive advanced solid tumors in a global multi-center phase Ia dose escalation trial.
Methods: In this phase Ia trial, a modified 3 + 3 study design was adopted during dose escalation phase. Eligible patients were enrolled, and GQ1001 monotherapy was administered intravenously every 3 weeks.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!